Advertisement
U.S. markets closed

BioNTech SE (22UA.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
85.34-0.06 (-0.07%)
At close: 07:22PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close85.40
Open84.82
Bid85.32 x N/A
Ask86.38 x N/A
Day's Range84.82 - 86.86
52 Week Range77.50 - 119.90
Volume1,314
Avg. Volume1,314
Market Cap20.383B
Beta (5Y Monthly)0.23
PE Ratio (TTM)22.28
EPS (TTM)3.83
Earnings DateMay 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 02, 2022
1y Target Est334.89
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 22UA.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Barrons.com

      This Vaccine Maker Sits on Cash Almost Equal to Its Market Value

      This biotechnology company has nearly 90% of its market value in cash and investments but is being shunned by investors even as they gravitate to the sector this year. The company is BioNTech (Ticker BNTX). It partnered with Pfizer to produce the leading Covid vaccine, Comirnaty, whose original messenger RNA technology was developed by BioNTech.

    • Reuters

      UPDATE 2-BioNTech gets US agency notice over default on COVID vaccine royalties

      BioNTech said on Monday the U.S. National Institutes of Health has sent a notice to the German company regarding default on the payment of royalties and other amounts related to its COVID-19 vaccine. BioNTech, which partnered with U.S. pharma giant Pfizer for its COVID-19 vaccine, however, said it disagreed with the positions being taken by the NIH and intends to defend against all allegations of breach. Spokespersons for the U.S. NIH did not immediately respond to Reuters' request for a comment.

    • Simply Wall St.

      BioNTech Full Year 2023 Earnings: Misses Expectations

      BioNTech ( NASDAQ:BNTX ) Full Year 2023 Results Key Financial Results Revenue: €3.82b (down 78% from FY 2022). Net...